Provided by Tiger Trade Technology Pte. Ltd.

Tredegar

6.66
-0.0600-0.89%
Volume:23.23K
Turnover:155.95K
Market Cap:232.51M
PE:6.96
High:6.72
Open:6.72
Low:6.65
Close:6.72
52wk High:10.53
52wk Low:6.25
Shares:34.91M
Float Shares:28.20M
Volume Ratio:3.26
T/O Rate:0.08%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.9572
EPS(LYR):0.9604
ROE:15.47%
ROA:6.50%
PB:1.02
PE(LYR):6.93

Loading ...

TG Therapeutics Announces Publication of Post-Hoc Data from the Phase 3 ULTIMATE I & II Trials in Treatment Naive Patients with Relapsing Forms of MS Published in Frontiers in Immunology

GlobeNewswire
·
Jun 01

TG Metals Advances Lake Johnston Lithium Project with Burmeister Mining Lease Application

TIPRANKS
·
Jun 01

Tredegar 10% owner William M. Gottwald sells shares worth $163,148.35

Reuters
·
May 29

Tredegar 10% owner James T. Gottwald reports sale of 20,496 common shares worth $164,231

Reuters
·
May 29

TG Metals Starts Drilling to Expand Van Uden Laterite Gold Resource

TIPRANKS
·
May 28

Tredegar Announces Board Changes and New Independent Director

TIPRANKS
·
May 28

Tredegar names Joseph Haniford independent director as two board members step down

Reuters
·
May 28

Tredegar Announces Director Transitions

THOMSON REUTERS
·
May 28

TG Therapeutics Price Target Maintained With a $70.00/Share by HC Wainwright & Co.

Dow Jones
·
May 28

TG Therapeutics reports ENHANCE trial meets primary endpoint

TIPRANKS
·
May 27

New REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated Patients with Hypertriglyceridemia

GlobeNewswire
·
May 27

TG Therapeutics Announces Positive Topline Results from Phase 3 ENHANCE Trial

GlobeNewswire
·
May 27

Tredegar names Susan Sweeney as chief human resources officer effective June 1, 2026

Reuters
·
May 27

Tredegar Corporation Announces Susan Sweeney Joins Company as Vice President and Chief Human Resources Officer

THOMSON REUTERS
·
May 27

Tredegar 10% owner James T. Gottwald disposes of 141 shares for $1,128

Reuters
·
May 27

TG Therapeutics Announces Data Presentations for BRIUMVI® at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting

GlobeNewswire
·
May 26

How Investors May Respond To TG Therapeutics (TGTX) Boosting 2026 Guidance On Stronger Briumvi Sales

Simply Wall St.
·
May 24

Tredegar CEO Arijit DasGupta acquires $7,550 in common shares

Reuters
·
May 22

TG Therapeutics Raises 2026 Outlook As Briumvi Drives Concentrated Growth

Simply Wall St.
·
May 22

Insider Shake-Up at Tredegar: Director’s Stock Sale Draws Investor Attention

TIPRANKS
·
May 21